Why Veradigm Is Buying ScienceIO For $140 Million

By Amit Chowdhry • Feb 28, 2024

Veradigm – a leading provider of healthcare data and technology products and solutions – announced that it has signed a definitive agreement to acquire ScienceIO. The Veradigm Board of Directors has unanimously approved the deal and is expected to close as promptly as practicable following the satisfaction of customary closing conditions.

Launched in 2019, ScienceIO is a leading AI platform and foundation model provider for healthcare. ScienceIO’s models power diverse healthcare use cases while preserving patient privacy – including patient anonymization, record linkage, information extraction, summarization, and predictive analytics.

Through the acquisition, Veradigm expects to:

  • Utilize ScienceIO’s AI platform to create its own proprietary large language models on Veradigm’s rich data set – which spans a comprehensive network of over 400,000 providers and over 200 million patients, while ensuring data integrity and patient privacy;
  • Fast-track the launch of new features across Veradigm’s business to enhance the customer experience. This injection of AI is an investment across the whole Veradigm portfolio, including the Provider, Payer, and Life Science businesses;
  • Provide the company with a growth engine for the future by repositioning Veradigm as a leader in the healthcare data intelligence market
  • Ultimately, it delivers greater value for customers and better outcomes to patients throughout the healthcare ecosystem.

The deal will be funded through cash on hand and is not subject to a financing condition. The purchase price to be paid for ScienceIO is $140 million in cash (subject to customary adjustments for cash, indebtedness, working capital, and transaction expenses), an aggregate of approximately $44 million of which is deferred and substantially all of which is payable in installments on each of the first three anniversaries of the closing date.

KEY QUOTES:

“Our core business continues to be strong, profitable and healthy, and we are accelerating our growth strategy with this acquisition. Veradigm has built one of the most unique and valuable assets in the healthcare industry: a large-scale, high-quality data set that spans providers, payers and life sciences companies. By building on our existing partnership and fully integrating ScienceIO’s AI platform, we will be able to extract greater and more accurate insights from this data set and build an AI center of excellence to empower Veradigm’s portfolio across all of our business units with market-leading capabilities. In doing so, we will be able to provide more highly differentiated and advanced products to provider, payer and life sciences customers that ultimately result in higher quality, lower cost care for patients, while positioning Veradigm as a higher-margin technology and data products company poised for future growth and value creation.”

  • Yin Ho, Veradigm’s Interim CEO and a member of the company’s board

 “This acquisition is a natural next step in the strategy our Board has been focused on over the past year to drive continued growth across our business units and create outsized value from the data and analytics of our existing business, while maintaining our healthy balance sheet and strong cash position. We will be at the center of the largest platform shift in healthcare as the industry becomes increasingly focused on value-based care while also reducing administrative burden. The Board has full confidence in Yin and our President, Tom Langan, to lead the Company through this transformation.”

  • Greg Garrison, Executive Chairman of the Veradigm Board

“Together with Veradigm, we will provide new features and capabilities for providers and partners, accelerated by ScienceIO’s differentiated AI platform. Joining Veradigm aligns with ScienceIO’s mission to better serve patients and healthcare professionals with the help of responsible AI. We are thankful for our partners who made this moment possible and we look forward to bringing together our combined strengths to drive innovation and value in the healthcare ecosystem.”

  • Will Manidis, CEO of ScienceIO